Biomarkers for Cancer Treatment

To identify and validate changes in miRNA pre- and post- radical RT/chemo-RT (cohort 1) and pre- and post- IO-based complex SACT (cohort 2) and elucidate links between dysregulated miRNAs and clinical evaluations.

To identify and validate changes in protein biomarker profile (1,034 protein targets) pre- and post- radical RT/chemo-RT (cohort 1) and pre- and post- IO-based complex SACT (cohort 2) and to elucidate links between changes in proteins relevant to immune and inflammatory pathways and clinical evaluations.

Inclusion criteria

• Adult patients (Age >18 years)
• Histologically/Cytological confirmed solid tumour
• Treated with radical RT or concurrent chemo-RT (Cohort 1) OR
• Treated with chemo-IO or IO-IO combination (Cohort 2)
• First-line treatment
• Able to provide informed consent
• Willing to comply with study procedures

Exclusion criteria

• Contraindication for RT or chemotherapy (Cohort 1) OR
• Contraindication for chemotherapy or IO (Cohort 2)
• Use of chemotherapy or immunotherapy in the last 5 years. (Cohort 1) OR
• Use of radical RT or chemo-RT within the thorax in the last 5 years. (Cohort 2)
• Beyond first-line treatment (second line onwards)
• Has more than 1 active cancer requiring treatment
• Recent participation in an interventional study
• Pregnant or breastfeeding women
• On long term cytotoxics or immune-modulators for rheumatoid arthritis or connective tissue disorders or auto-immune disorders
• Poor life expectancy, likely less than 6 months
• Patients not likely to comply with treatment or the study